Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis

Neurology

Volumn 68, Issue 22 SUPPL. 3, 2007, Pages

  Dhib Jalbut, Suhayl ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; RILUZOLE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; DRUG DOSE COMPARISON; HUMAN; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA;

EID: 34249803582     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000275228.13012.7b     Document Type: Conference Paper

References (44)

1. Dhib-Jalbut S, Arnold DL, Cleveland DW, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 2006;176:198-215.
2. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De-Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005;204:208-231.
3. Quandt JA, Baig M, Yao K, et al. Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med 2004;200:223-234.
4. Hemmer B, Fleckenstein BT, Vergelli M, et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997;185:1651-1659.
5. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
6. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med 2000;6:1167-1175.
7. Kappos L, Comi G, Panitch H, et al., and The Altered Peptide Ligand in Relapsing MS Study Group. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Med 2000;6:1176-1182.
8. Olson JK, Ludovic Croxford J, Miller SD. Innate and adaptive immune requirements for induction of autoimmune demyelinating disease by molecular mimicry. Mol Immunol 2004;40:1103-1108.
9. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63-66.
10. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
11. Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis. J Neuroimmunol 2000;111:186-194.
12. Graber J, Zhan M, Ford D, et al. Interferon β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005;161:169-176.
13. Polman CH, O'Connor PW, Havrdova E, et al., for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
14. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain 1999;122:191-197.
15. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397-1401.
16. Trojano M, Avolio C, Liuzzi GM, et al. Changes in serum sICAM-1 and MMP-9 induced by rINFβ-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-1408.
17. Özenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β. J Neuroimmunol 2000;108:236-243.
18. Karabudak R, Kurne A, Guc D, Sengelen M, Canpinar H, Kansu E. Effect of interferon β-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. J Neurol 2004;251:279-283.
19. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-1308.
20. Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J Neurosci Res 2005;81:363-373.
21. Antel J. Oligodendrocyte/myelin injury and repair as a function of the central nervous system environment. Clin Neurol Neurosurg 2006;108:245-249.
22. Vowinckel E, Reutens D, Becher B, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997;50:345-353.
23. Barnnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-468.
24. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 2003;100:8514-8519.
25. Ekdahl CT, Claasen J-H, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003;100:13632-13637.
26. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin Neurol Neurosurg 2004;106:223-229.
27. Killestein J, Kalkers N, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 2005;233:113-115.
28. Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol 2004;151:171-179.
29. Encinas JM, Manganas L, Enikolopov G. Nitric oxide and multiple sclerosis. Curr Neurol Neurosci Rep 2005;5:232-238.
30. Parkin J, Cohen B. An overview of the immune system. Lancet 2001;357:1777-1789.
31. Abdul-Majid K-B, Stefferl A, Bourquin C, et al. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand J Immunol 2002;55:70-81.
32. Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy? J Neuroimmunol 2002;131:5-20.
33. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
34. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-145.
35. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-621.
36. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-979.
37. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003;100:14157-14162.
38. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003;215:37-44.
39. Dhib-Jalbut S, Chen M, Said A, Zhan M, Johnson KP, Martin R. Glatiramer acetate-reactive blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 2003;140:163-171.
40. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005;4:567-575.
41. Comi G, Filippi M, Wolinsky JS, for the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49;290-297.
42. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005;102:6449-6454.
43. Allie R, Hu L, Mullen KM, Dhib-Jalbut S, Calabresi PA. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol 2005;62:889-894.
44. Valenzuela RM, Costello K, Johnson KP, Dhib-Jalbut S. Ex-vivo cellular IL-4/IFN-gamma ratio correlates with clinical response to glatiramer acetate (Copaxone) in multiple sclerosis. Neurology 2005;64(suppl 1):A418. Abstract.